The drug coverage provision does not mention any specific drug by name, but it could include the GLP-1 agonists, such as ...

The first study to put two GLP-1 weight loss drugs head-to-head found Zepbound helped people lose more weight than Wegovy.

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

The move follows a dramatic breakup in June between Hims & Hers and Danish drug maker Novo Nordisk, which makes the brand name weight loss drug Wegovy. Novo Nordisk accused the Hims & Hers of ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

A recent survey highlighted a widespread lack of understanding about the much-publicised GLP-1 weight-loss medications ...

Novo Nordisk seeks EMA approval for 7.2 mg Wegovy dose after trials show 21% weight loss in people with obesity and type 2 diabetes.

The recent approval of weight-loss drug Wegovy in New Zealand has been hyped as a breakthrough in the country’s fight against ...

"Beyond weight loss, Wegovy has shown cardiovascular benefits such as reducing the risk of major adverse cardiovascular events in obese or overweight patients with heart disease," says Dr. Emch.

“Beyond weight loss, Wegovy has shown cardiovascular benefits such as reducing the risk of major adverse cardiovascular events in obese or overweight patients with heart disease,” says Dr. Emch.

If insurance doesn’t cover Ozempic or Wegovy for weight loss, the average monthly price is $1,430, according to Drugs.com. People may need to stop due to side effects, cost or health issues.

Novo Nordisk has introduced Wegovy, a once-weekly weight-loss injection, in India. The drug aims to manage obesity and reduce ...